Capecitabine in the treatment of esophageal and gastric cancers

Bibliography

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41
   PubMed Web of Science ®Google Scholar
• Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355-63
   PubMed Web of Science ®Google Scholar
• Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998;16(5):1795-802
   PubMed Web of Science ®Google Scholar
• Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40(2):85-104
   PubMed Web of Science ®Google Scholar
• Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003;6(1):2-8
   PubMedGoogle Scholar
• Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55(7):1091-7
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001;18(8):1190-202
   PubMed Web of Science ®Google Scholar
• Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Inoue Y, Nagashima N, et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res 2005;25(6A):3755-61
   PubMed Web of Science ®Google Scholar
• Koizumi W, Okayasu I, Hyodo I, Sakamoto J, et al. Clinical Study Group of C. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs 2008;19(8):819-24
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282-92
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-106
   PubMed Web of Science ®Google Scholar
• Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002;49(3):225-34
   PubMed Web of Science ®Google Scholar
• Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999;5(7):1696-702
   PubMed Web of Science ®Google Scholar
• Park J-Y, Kim K-A. Inhibitory effect of 5-fluorouracil on human cytochrome P450 isoforms in human liver microsomes. Eur J Clin Pharmacol 2003;59(5-6):407-9
   PubMed Web of Science ®Google Scholar
• Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol 2006;98(2):197-200
   PubMed Web of Science ®Google Scholar
• Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010;13(1):1-10
   PubMed Web of Science ®Google Scholar
• Tan IB, Ivanova T, Lim KH, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011;141(2):476-85. e11
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52(7):797-805
   PubMed Web of Science ®Google Scholar
• Bria E, De Manzoni G, Beghelli S, et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 2013;24(3):693-701
   PubMed Web of Science ®Google Scholar
• Kiyose S, Nagura K, Tao H, et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int 2012;62(7):477-84
   PubMed Web of Science ®Google Scholar
• Ruschoff J. Adenocarcinoma of the GEJ: gastric or oesophageal cancer? Recent Results Cancer Res 2012;196:107-13
   PubMedGoogle Scholar
• Hong Y, Song S, Lee S, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004;15(9):1344-7
   PubMed Web of Science ®Google Scholar
• Sakamoto J, Chin K, Kondo K, et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006;17(2):231-6
   PubMed Web of Science ®Google Scholar
• Sawada N, Kondoh K, Mori K. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Oncol Rep 2007;18(4):775-8
   PubMed Web of Science ®Google Scholar
• Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005;92(11):1976-83
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358(1):36-46
   PubMed Web of Science ®Google Scholar
• Kang Y-K, Kang W-K, Shin D-B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20(4):666-73
   PubMed Web of Science ®Google Scholar
• Okines A, Norman A, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20(9):1529-34
   PubMed Web of Science ®Google Scholar
• Lee J, Im YH, Cho EY, et al. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008;62(1):77-84
   PubMed Web of Science ®Google Scholar
• Giordano KF, Jatoi A, Stella PJ, et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006;17(4):652-6
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4(4):1013-19
   PubMed Web of Science ®Google Scholar
• Lo SS, Khorana AA, Javle M, et al. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology 2010;78(2):125-9
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Dogan Y, et al. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer 2011;105(4):505-12
   PubMed Web of Science ®Google Scholar
• Yun T, Han JY, Lee JS, et al. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer 2011;11:385
   PubMedGoogle Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991-7
   PubMed Web of Science ®Google Scholar
• Shah M, Shibata S, Stoller R, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol (Meeting Abstracts) 2010;2010:4014
   Google Scholar
• Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24(18):2903-9
   PubMed Web of Science ®Google Scholar
• Luo HY, Wang ZQ, Wang FH, et al. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol 2011;34(6):555-60
   PubMed Web of Science ®Google Scholar
• Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21(1):71-7
   PubMed Web of Science ®Google Scholar
• Sun Q, Hang M, Xu W, et al. Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol 2009;39(12):791-6
   PubMed Web of Science ®Google Scholar
• Farhat FS, Kattan J, Ghosn MG. Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. Expert Rev Anticancer Ther 2010;10(4):541-8
   PubMed Web of Science ®Google Scholar
• Bajetta E, Verzoni E, Ferrario E, et al. Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori 2009;95(1):43-7
   PubMed Web of Science ®Google Scholar
• Brell JM, Krishnamurthi SS, Javle M, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol 2009;63(5):851-7
   PubMed Web of Science ®Google Scholar
• Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 2005;94(2):281-6
   Web of Science ®Google Scholar
• Lu M, Gao J, Wang X-C, Shen L. Expressions of thymidylate synthase, thymidine phosphorylase, class III beta-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chin J Cancer Res 2011;23(4):288-94
   PubMed Web of Science ®Google Scholar
• Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008;8:386
   PubMed Web of Science ®Google Scholar
• NCCN. National Comprehensive Cancer Network Guidelines- Gastric Cancer Version 2.2013. National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf [Accessed 8.2013]
   Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14(6):481-9
   PubMed Web of Science ®Google Scholar
• Lordick F, Kang Y-K, Chung H-C, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14(6):490-9
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30):3968-76
   PubMed Web of Science ®Google Scholar
• Shah MA, Van Cutsem E, Kan Y, et al. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. J Clin Oncol (Meeting Abstracts) 2012;2012
   Google Scholar
• Hecht JR, Bang YJ, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial. J Clin Oncol 2013;31(Suppl):abstract#LBA4001
   Google Scholar
• Shionoya M, Jimbo T, Kitagawa M, et al. DJ-927, a novel oral taxane, overcomes P‐glycoprotein‐mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94(5):459-66
   PubMed Web of Science ®Google Scholar
• Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30(19):2327-33
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357(18):1810-20
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366(22):2074-84
   PubMed Web of Science ®Google Scholar
• Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27(30):5062-7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11-20
   PubMed Web of Science ®Google Scholar
• Reece-Smith AM, Saha S, Cunnell ML, et al. MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas. J Surg Oncol 2012;106(6):748-52
   PubMed Web of Science ®Google Scholar
• Cassidy J, Saltz L, Twelves C, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol 2011;22(12):2604-9
   PubMed Web of Science ®Google Scholar
• Bonenkamp J, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340(12):908-14
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379(9813):315-21
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Hofheinz RD, Arnold D, et al. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Ann Oncol 2012;23(11):2827-34
   PubMed Web of Science ®Google Scholar
• Polyzos A, Felekouras E, Karatzas T, et al. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Anticancer Res 2012;32(9):4151-6
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15(1):261-7
   PubMed Web of Science ®Google Scholar
• Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;3:3
   PubMedGoogle Scholar
• Vaishampayan UN, Ben-Josef E, Philip PA, et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002;53(3):675-9
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (xeloda) in human cancer xenografts. Clin Cancer Res 1999;5(10):2948-53
   PubMed Web of Science ®Google Scholar
• ‚ Roh M, Yothers GOO'Connell M, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011;29(18 Suppl):3503
   PubMed Web of Science ®Google Scholar
• Hofheinz R, Wenz F, Post S, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-) adjuvant chemo-radiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial. Onkologie 2011;34:199-9
   PubMed Web of Science ®Google Scholar
• Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462-7
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26(7):1086-92
   PubMed Web of Science ®Google Scholar
• Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8(3):226-34
   PubMed Web of Science ®Google Scholar
• Osti MF, Agolli L, Bracci S, et al. Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection. Anticancer Res 2012;32(4):1397-402
   PubMed Web of Science ®Google Scholar
• Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30(3):268-73
   PubMed Web of Science ®Google Scholar
• Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011;11:329
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Wenz F, Lukan N, et al. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer–an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 2009;73(1):142-7
   PubMed Web of Science ®Google Scholar
• Boda-Heggemann J, Weiss C, Schneider V, et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 2013;189(5):417-23
   PubMed Web of Science ®Google Scholar
• Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 2009;27(2):193-200
   PubMed Web of Science ®Google Scholar